India, Jan. 23 -- Sun Pharmaceutical Industries Limited announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection in India for chronic weight management in adults.
Semaglutide, a GLP-1 receptor agonist, is indicated as an adjunct to a reduced-calorie diet and increased physical activity. Sun Pharma will launch the product under the brand name Noveltreat after the expiry of the semaglutide patent in India.
The approval follows a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths—0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL—with a recommen...